SCHEMBL4889084

SCHEMBL4889084

CC(O)c1cnc(Nc2cccc(F)c2)nc1C(F)(F)F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 8/20 0.54
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
SYK P43405 2/20 0.44
CDK4 P11802 2/20 0.44
CCND1 P24385 1/20 0.44
CCND2 P30279 1/20 0.44
CCND3 P30281 1/20 0.44
GRM5 P41594 1/20 0.44
CTSC P53634 1/20 0.42
TBK1 Q9UHD2 1/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
AURKA O14965 1/20 0.41
CDK2 P24941 2/20 0.41
CDC7 O00311 1/20 0.41
DAPK3 O43293 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4896414 0.87 CNR2 (0.56) CNR2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4894744 0.83 CNR2 (0.50) CNR2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4893291 0.82 CNR2 (0.47) CNR2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4895532 0.80 CNR2 (0.52) CNR2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4894731 0.80 CNR2 (0.67) CNR2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4890233 0.80 CNR2 (0.50) CNR2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4886226 0.79 CNR2 (0.61) CNR2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL3378853 0.78 CNR2 (0.72) CNR2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4889039 0.78 CNR2 (0.65) CNR2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4893853 0.78 CNR2 (0.59) CNR2CYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261977-A1 Pyrimidine Derivatives as Cannabinoid Receptor Modulators GLAXO GROUP LIMITED (GB) 2008-10-23 US disclosed
US-20080261977-A1 Pyrimidine Derivatives as Cannabinoid Receptor Modulators GLAXO GROUP LIMITED (GB) 2008-10-23 US disclosed
US-20080261977-A1 Pyrimidine Derivatives as Cannabinoid Receptor Modulators GLAXO GROUP LIMITED (GB) 2008-10-23 US disclosed
EP-1718620-A1 PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2006-11-08 EP disclosed
WO-2005080350-A1 PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261977-A1 Pyrimidine Derivatives as Cannabinoid Receptor Modulators CNR2, CNR1, P2RY2 CNR2 1/4885CYP1A2 749/4885CYP3A4 1614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.